

# Information Regarding Clinical Trial

<b>Title</b>	Phase 2, non-randomized, open label, single arm, multi-center study of Talazoparib for neoadjuvant treatment of germline BRCA ½ Mutation patients with early triple neg breast CA
<b>Protocol Number</b>	C3441020
<b>Sponsor</b>	Pfizer
<b>Investigator</b>	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
<b>Study Related Phone Numbers</b>	479-587-1700 (24 hours)
<b>Key Points for Study</b>	consent to BRCA analysis test with Myriad genetics -TNBC as defined: ER/PR less than 10%, HER2 by IHC as 0 or 1+ -Tumor >1.5cm, no evidence of distant metastasis -see locally advanced disease -see adequate bone marrow, hepatic, renal function, -ECOG 0 or 1 -Available archival tumor tissue; if none available must have fresh tumor biopsy see women of childbearing potential section